Anavex Life Sciences Corp (AVXL)

[Investor2014]

Now there is good question.

Long term, like 3+ years from now, I do think we could have approval for A2-73 in Rett bagged and revenue. Hopefully before based on EXCELLENCE.

During the next 3 years we could have P3 Precision Medicine trials fully enrolled for PD/PPD and AD. Those trials could be very well designed enrolling just the right patients for A2-73.

Those PM trials will be a little harder to enroll for given genetic screening and selection cutting down on the number that can be included vs. screened. On the other hand those trials many not need a huge n, maybe about n = 300, to be powered for succes.

A best scenario is then Rett, PD/PDD and AD in the bag fully approved end 2027. All the while with some rare disease revenue.

A3-71 one for me is too early to make guesses on. Clinically we don't know more than P1 safety at the moment.

We could also have Fragile X and who knows what else running in parallel with this.

Of course given the time horizon, there could be interveners with something even better, but none that I would rate in the clinic just now.